Literature DB >> 7911579

Reduction of rat pup ultrasonic vocalizations by the neuroactive steroid allopregnanolone.

B Zimmerberg1, S A Brunelli, M A Hofer.   

Abstract

Several of the recently characterized neuroactive steroids have been proposed to have anxiolytic effects in behavioral models when subjects were tested as adults. In this experiment, the effects on infant subjects were examined using the isolation distress model of anxiety. The production of ultrasonic vocalizations in week-old rat pups after maternal separation was assessed after ICV injections of vehicle or allopregnanolone (1.25-5 micrograms), or sham injections. Subjects were also observed for activity and behavioral responses and tested on three measures of sedation. Allopregnanolone caused a dose-dependent decrease in ultrasonic vocalizations, with increasing motor incoordination, ataxia, and turning at the higher doses. Sex differences were not observed for any measure. These results suggest the GABAA receptor binding site for neuroactive steroids is behaviorally active in neonates as well as in adults, and that the anxiolytic effects of the neuroactive steroids at this site may be dissociable from their sedative effects at low doses.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911579     DOI: 10.1016/0091-3057(94)90181-3

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  13 in total

1.  Maternal care modulates transgenerational effects of endocrine-disrupting chemicals on offspring pup vocalizations and adult behaviors.

Authors:  Krittika Krishnan; Shafaqat Rahman; Asbiel Hasbum; Daniel Morales; Lindsay M Thompson; David Crews; Andrea C Gore
Journal:  Horm Behav       Date:  2019-01-04       Impact factor: 3.587

Review 2.  Acquisition and expression of a socially mediated separation response.

Authors:  Harry N Shair
Journal:  Behav Brain Res       Date:  2007-02-20       Impact factor: 3.332

Review 3.  Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics.

Authors:  K A Miczek; E M Weerts; J A Vivian; H M Barros
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

4.  Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events.

Authors:  V K Patchev; A Montkowski; D Rouskova; L Koranyi; F Holsboer; O F Almeida
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  Administration of clozapine to a mother rat potentiates pup ultrasonic vocalization in response to separation and re-separation: contrast with haloperidol.

Authors:  Ming Li; Wei He; Katherine Heupel
Journal:  Behav Brain Res       Date:  2011-04-05       Impact factor: 3.332

6.  Social closeness increases salivary progesterone in humans.

Authors:  Stephanie L Brown; Barbara L Fredrickson; Michelle M Wirth; Michael J Poulin; Elizabeth A Meier; Emily D Heaphy; Michael D Cohen; Oliver C Schultheiss
Journal:  Horm Behav       Date:  2009-04-09       Impact factor: 3.587

Review 7.  Selective breeding for infant rat separation-induced ultrasonic vocalizations: developmental precursors of passive and active coping styles.

Authors:  Susan A Brunelli; Myron A Hofer
Journal:  Behav Brain Res       Date:  2007-04-27       Impact factor: 3.332

8.  Neurosteroids and GABA(A) Receptor Interactions: A Focus on Stress.

Authors:  Benjamin G Gunn; Adam R Brown; Jeremy J Lambert; Delia Belelli
Journal:  Front Neurosci       Date:  2011-12-05       Impact factor: 4.677

9.  Beyond the HPA Axis: Progesterone-Derived Neuroactive Steroids in Human Stress and Emotion.

Authors:  Michelle M Wirth
Journal:  Front Endocrinol (Lausanne)       Date:  2011-08-11       Impact factor: 5.555

10.  Behavioral and neurogenomic transcriptome changes in wild-derived zebrafish with fluoxetine treatment.

Authors:  Ryan Y Wong; Sarah E Oxendine; John Godwin
Journal:  BMC Genomics       Date:  2013-05-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.